Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab

• Verfasst von: Jensen, Alexandra [VerfasserIn]
• Verfasst von: Münter, Marc [VerfasserIn]
• Verfasst von: Bischoff, Helge G. [VerfasserIn]
• Verfasst von: Haselmann, Renate [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Huber, Peter E. [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Herfarth, Klaus [VerfasserIn]
• Titel: Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab
• Titelzusatz: the Near trial
• Verf.angabe: Alexandra D. Jensen, Marc W. Münter, Helge G. Bischoff, Renate Haselmann, Uwe Haberkorn, Peter E. Huber, Michael Thomas, Jürgen Debus, and Klaus K. Herfarth
• E-Jahr: 2011
• Jahr: 24 January 2011
• Umfang: 9 S.
• Fussnoten: Gesehen am 05.07.2022
• Titel Quelle: Enthalten in: Cancer
• Ort Quelle: New York, NY : Wiley-Liss, 1948
• Jahr Quelle: 2011
• Band/Heft Quelle: 117(2011), 13, Seite 2986-2994
• ISSN Quelle: 1097-0142
• DOI: doi:10.1002/cncr.25888
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cetuximab
• Sach-SW: elderly
• Sach-SW: IMRT
• Sach-SW: NSCLC
• Sach-SW: radioimmunotherapy
• K10plus-PPN: 1809113709

Abstract

BACKGROUND: The aim of this study was to evaluate efficacy and toxicity of radioimmunotherapy with intensity-modulated radiation (IMRT) and cetuximab in stage III nonsmall cell lung cancer (NSCLC). METHODS: NEAR was a prospective, monocentric phase II trial including patients unfit for chemoradiation regimen; treatment consisted of IMRT and weekly cetuximab followed by a 13-week maintenance period. Primary endpoints were toxicity and feasibility; secondary endpoints were remission rates at completion of the planned treatment according to Response Evaluation Criteria In Solid Tumor (RECIST), local/distant progression-free survival, and overall survival. RESULTS: Thirty patients (median age, 71 years) were treated within the protocol. Overall response rate was 63% (partial remission: 19 of 30) patients. Median locoregional, distant, overall progression-free survival was 20.5, 10.9, and 8.5 months. Median overall survival was 19.5 months, with an estimated 1- and 2-year survival of 66.7% and 34.9% respectively. Stage (IIIA vs IIIB) and histologic subtype did not have a significant impact on survival rates in our patients. Treatment was tolerated well with only mild toxicity (°3 pneumonitis: 3.3%, any °3 acute toxicity: 36.7%). CONCLUSIONS: Combined radioimmunotherapy with cetuximab was safe and feasible, especially in elderly patients with multiple comorbidities. A more intensified regimen warranted investigation.